Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine

Late onset neutropenia (LON) related to rituximab or rituximab plus chemotherapy is defined as an unexplained absolute neutrophil count of ≤1.5 × 10(9)/L starting at least four weeks after the last rituximab administration. LON is infrequent and its pathophysiology remains unknown. There are no guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Diez-Feijóo, Ramon, Rodríguez-Sevilla, Juan Jose, Fernández-Rodríguez, Concepcion, Flores, Solange, Raya, Carmen, Ferrer, Ana, Colomo, Luis, Salar, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784545/
https://www.ncbi.nlm.nih.gov/pubmed/35082788
http://dx.doi.org/10.3389/fimmu.2021.798251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784545/
https://www.ncbi.nlm.nih.gov/pubmed/35082788
http://dx.doi.org/10.3389/fimmu.2021.798251

Ejemplares similares